Oral Minoxidil vs Spironolactone for Hair Loss and Acne: Head-to-Head Efficacy for Women

What These Two Drugs Actually Do (and Why They're Often Compared)

Oral minoxidil and spironolactone end up in the same conversation because both are oral pills that women use off-label for hair loss, and dermatologists frequently choose between them. They share almost no pharmacology.

Oral minoxidil is a systemic vasodilator. Originally developed for hypertension, it opens ATP-sensitive potassium channels in vascular smooth muscle and, through a mechanism that is still not fully understood, extends the anagen (growth) phase of hair follicles and increases follicular size. At the low doses used for hair (0.25 to 2.5 mg daily), blood pressure effects are modest in most women but not zero.

Spironolactone blocks aldosterone receptors and, at the same doses, competitively inhibits androgen receptors and reduces 5-alpha-reductase activity. That dual anti-androgen action is why it works for both androgenetic alopecia and hormonal acne. It is not a vasodilator and does nothing to scalp blood flow.

Because the mechanisms differ, some clinicians combine them. The evidence for combination use is thin, but the logic is sound: one drug targets follicle biology directly while the other addresses the hormonal driver.

Efficacy for Female Pattern Hair Loss: What the Data Actually Show

No published randomized controlled trial has placed oral minoxidil and spironolactone in a direct head-to-head comparison for female pattern hair loss (FPHL). Every comparison you read, including this one, synthesizes separate trial data. That is an honest limitation you deserve to know upfront.

Oral Minoxidil: The Sinclair 2018 Evidence

The most-cited dataset for low-dose oral minoxidil in women comes from Sinclair's 2018 Australian cohort published in the Australasian Journal of Dermatology. In 100 women with FPHL treated with 0.25 mg to 5 mg daily, hair density improved in the majority of patients across the dose range, with meaningful response seen even at the lowest 0.25 mg dose. Hypertrichosis (unwanted body hair growth) was the main dose-limiting side effect, reported in roughly 18% of patients at 1 mg and increasing with higher doses. Fluid retention occurred in a small subset.

A 2022 systematic review published in the Journal of the American Academy of Dermatology pooled data across oral minoxidil studies and found that doses between 0.25 mg and 2.5 mg produced consistent hair density gains in women with minimal cardiovascular signal at those low doses. The authors noted that women metabolize minoxidil's active sulfate form differently depending on sulfotransferase enzyme activity, which partly explains why some women respond at 0.25 mg while others need 1 mg or more.

Spironolactone: Evidence for FPHL

Spironolactone's evidence base for FPHL is primarily retrospective. A widely cited 2017 review in the Journal of the American Academy of Dermatology found consistent evidence for hair retention and modest regrowth at doses of 100 to 200 mg daily in women with androgenetic alopecia, particularly those with elevated androgens or clinical signs of hyperandrogenism.

The FAAD (Female Androgenetic Alopecia) real-world dataset from Australia, published in Dermatology and Therapy, showed that women on spironolactone monotherapy had stabilization or improvement in approximately 74% of cases over 12 months. Response was stronger in women with biochemical or clinical androgen excess, which makes sense given the mechanism.

Putting the Numbers Side by Side

| Outcome | Oral Minoxidil | Spironolactone | |---|---|---| | Hair density gain | Yes, across doses 0.25 to 5 mg | Yes, primarily at 100 to 200 mg | | Works without androgen excess | Yes | Less clear; evidence is thinner | | Treats hormonal acne | No | Yes | | Time to response | 6 to 9 months | 3 to 6 months for acne; 9 to 12 months for hair | | Evidence level for FPHL | Prospective cohort + systematic review | Mostly retrospective cohorts |

The honest clinical read: oral minoxidil has more prospective evidence for hair density in unselected women with FPHL. Spironolactone has stronger mechanistic justification when androgen excess is confirmed, and it is the only one of the two that addresses acne at the same time.

Efficacy for Hormonal Acne: Spironolactone Wins This Category

Oral minoxidil has no meaningful evidence for acne and no biological reason to treat it. Spironolactone, on the other hand, has a large and growing evidence base specifically for hormonal acne in adult women.

The Evidence for Spironolactone in Acne

The SAHA trial (Layton et al., British Journal of Dermatology, 2021) randomized 410 adult women with facial acne to spironolactone 50 mg or 100 mg vs placebo. At 24 weeks, the Investigator Global Assessment clear or almost-clear rate was 44% in the 100 mg group vs 28% in the placebo group. Inflammatory lesion counts dropped significantly across both dose groups. This is the most rigorous RCT of spironolactone for acne in adult women to date.

Spironolactone is particularly effective for the pattern most women recognize: jawline and chin breakouts that flare in the week before menstruation. A retrospective study of 110 women found that 66% reported at least 50% reduction in acne at doses of 50 to 100 mg over six months.

PCOS: When Both Issues Coexist

Women with PCOS frequently deal with androgenic alopecia and acne at the same time. Spironolactone addresses both from a single mechanism, which gives it a practical advantage in this population. ACOG's 2018 Practice Bulletin on PCOS lists spironolactone as an option for managing androgen-related symptoms including hirsutism and acne, though it does not name it as first-line for hair loss specifically.

For a woman with PCOS who is bothered by hair thinning, acne, and possibly hirsutism, spironolactone is a reasonable single-agent approach. Oral minoxidil would need to be added separately if the hair response is insufficient.

Dosing, Titration, and Monitoring

Oral Minoxidil Dosing in Women

Most dermatologists start women at 0.25 mg to 1 mg daily, which is far below the cardiovascular doses (10 to 40 mg daily) used for refractory hypertension. Titration upward to 2.5 mg is reasonable if the lower dose is tolerated but response is incomplete after six months. Doses above 2.5 mg increase hypertrichosis risk sharply.

Monitoring includes baseline blood pressure, heart rate, and a review of any cardiac history. Women with pre-existing low blood pressure or those taking other antihypertensives need closer monitoring.

Spironolactone Dosing in Women

Starting doses for hair or acne are typically 25 to 50 mg daily, with titration to 100 mg over four to eight weeks depending on tolerability. For acne, 100 mg is the most evidence-supported dose. Hair loss responses at doses below 100 mg are less consistent.

Monitoring includes serum potassium, especially if you take ACE inhibitors or NSAIDs regularly. Women over 45 with any degree of kidney impairment need baseline electrolytes. The FDA label cautions about hyperkalemia, though this risk is very low in young, healthy women without kidney disease.

Sex-Specific Physiology: How Your Hormones Change the Picture

Menstrual Cycle Effects

Spironolactone can disrupt menstrual cycles, particularly at doses of 100 mg or higher. Irregular bleeding is reported in approximately 10 to 20% of premenopausal women on spironolactone monotherapy. Many dermatologists co-prescribe a combined oral contraceptive pill (OCP) for two reasons: cycle regulation and contraception (mandatory because of teratogen risk). The OCP also adds its own anti-androgen benefit through sex-hormone-binding globulin elevation.

Oral minoxidil does not directly affect menstrual cycling.

Perimenopause and Postmenopause

During perimenopause, fluctuating estrogen and rising androgen-to-estrogen ratios accelerate FPHL. Both drugs remain relevant. Spironolactone's anti-androgen effect may be less pronounced after menopause when absolute androgen levels fall, though some postmenopausal women still respond. Oral minoxidil works independently of hormonal milieu, making it a reliable option across the menopause transition.

Postmenopausal women on spironolactone no longer need to worry about menstrual irregularity but still need electrolyte monitoring, particularly if blood pressure medication is also in the picture.

PCOS and Elevated Androgens

Women with documented androgen excess (elevated free testosterone, DHEA-S, or clinical hyperandrogenism) are the strongest candidates for spironolactone. The anti-androgen mechanism directly targets the driver of their hair loss and acne. In contrast, oral minoxidil works regardless of androgen status, which is useful when androgen levels are normal but hair loss is still progressing.

Pregnancy, Lactation, and Contraception: Read This Section

Both drugs are contraindicated in pregnancy. This is not a mild advisory. It requires reliable contraception for any woman of reproductive potential taking either medication.

Oral Minoxidil in Pregnancy and Lactation

Oral minoxidil is FDA Pregnancy Category C, based on animal teratogenicity data. Human data are limited to case reports and small series, mostly at cardiovascular doses. At low doses used for hair, human teratogenicity data are essentially absent, but the risk cannot be excluded. The drug passes into breast milk; neonatal hypertrichosis and possible cardiovascular effects are theoretical concerns, and breastfeeding while taking oral minoxidil is not recommended.

Stop oral minoxidil before any planned pregnancy. If pregnancy occurs on the drug, discontinue immediately and consult your OB-GYN.

Spironolactone in Pregnancy and Lactation

Spironolactone carries the most urgent pregnancy warning of the two. It is FDA Pregnancy Category D and is known to feminize male fetuses in animal models by blocking androgen receptors at a critical developmental window. While data in human pregnancies at low doses are limited, the biological mechanism is plausible and concerning enough that all major guidelines, including ACOG, require reliable contraception throughout treatment.

Spironolactone is excreted in breast milk. Its active metabolite canrenone transfers to the infant. Breastfeeding while taking spironolactone is generally not recommended.

Contraception summary for both drugs: use a method with <1% typical-use failure rate. Many prescribers pair spironolactone with a combined OCP, which solves both the contraception requirement and the cycle-regulation issue. An IUD is an acceptable alternative.

Side Effects: What Women Actually Report

Oral Minoxidil Side Effects

The side effect that most often limits oral minoxidil in women is hypertrichosis, meaning increased hair growth on the face, arms, or legs. It appears in roughly one in six women at 1 mg and is more common at higher doses. It is largely reversible on stopping the drug.

Other reported effects include:

• Fluid retention, ankle swelling (more common at doses above 2.5 mg)
• Reflex tachycardia (fast heart rate), usually mild at low doses
• Pericardial effusion (rare, associated with higher doses and pre-existing kidney disease)
• Headache

Most women tolerate 0.25 to 1 mg with minimal cardiovascular effects. A 2023 safety review in JAMA Dermatology of over 1,400 patients on low-dose oral minoxidil found the rate of clinically significant cardiovascular adverse events was <1% at doses of 5 mg or below.

Spironolactone Side Effects

• Menstrual irregularity (10 to 20% of premenopausal women, dose-dependent)
• Breast tenderness or enlargement
• Fatigue, especially early in treatment
• Polyuria (increased urination) from the diuretic effect
• Hyperkalemia, low in healthy young women but real in those with kidney disease
• Dizziness or orthostatic hypotension at higher doses

Spironolactone does not cause hypertrichosis. That alone makes it preferable for women who are already bothered by body hair.

Who This Is Right For (and Who Should Avoid Each Drug)

Oral Minoxidil: Best Fit

You are likely a good candidate for oral minoxidil if you have FPHL regardless of hormone status, if your androgens are normal but hair loss is progressing, if you are postmenopausal and spironolactone's electrolyte risks feel less worth taking on, or if topical minoxidil has worked but scalp application is inconvenient. Women who already have noticeable facial or body hair should think carefully before starting, given hypertrichosis risk.

Spironolactone: Best Fit

Spironolactone fits best when you have confirmed or suspected androgen excess (PCOS, elevated DHEA-S, or clinical hirsutism), when you want to treat FPHL and hormonal acne with one pill, or when you are in the perimenopausal years with jawline acne that flares cyclically. It is also a strong option when you are already using a combined OCP and need something to add for androgens.

Women Who Should Avoid Each Drug

Avoid oral minoxidil if you have significant cardiovascular disease, poorly controlled hypertension (counterintuitive but true: erratic dosing in this population can cause rebound hypertension), or a history of pericardial effusion.

Avoid spironolactone if you have chronic kidney disease (CKD stage 3 or worse), consistently elevated serum potassium, or if you are unwilling or unable to use reliable contraception. Spironolactone is also not appropriate during pregnancy attempts.

Neither drug is appropriate during pregnancy or breastfeeding.

Combination Therapy: Is There a Role for Both?

Some dermatologists prescribe both simultaneously, with the reasoning that minoxidil directly stimulates follicle growth while spironolactone removes the androgen brake on those same follicles. A 2021 retrospective series published in the International Journal of Dermatology found that women on combined oral minoxidil plus spironolactone showed numerically greater hair density improvement than either agent alone, though the study was small and uncontrolled.

WomanRx editorial board member Dr. Rachel Goldberg notes: "In my practice, I often start with spironolactone alone in younger women with PCOS-related hair loss, and add low-dose oral minoxidil at six months if density improvement is incomplete. The combination addresses both the hormonal driver and the follicle biology directly, and most women tolerate both drugs well together."

Combination therapy is off-label and not yet supported by randomized data. Both drugs still carry their individual pregnancy warnings, and contraception remains non-negotiable.

Switching Between the Two Drugs

Switching is straightforward from a pharmacological standpoint. Neither drug requires tapering before the other is started, though many clinicians overlap for a month to avoid any gap in treatment effect.

If you are switching from oral minoxidil to spironolactone because of hypertrichosis, expect the excess hair to gradually decrease over three to six months after stopping minoxidil. Hair density gains from minoxidil may partially reverse over the same period, so starting spironolactone before stopping minoxidil is the common approach.

If you are switching from spironolactone to oral minoxidil (for example, because you are entering a pregnancy attempt), stop spironolactone first, confirm negative pregnancy test, use barrier contraception, and discuss the oral minoxidil timing with your prescriber. Most clinicians advise stopping both drugs at least one month before stopping contraception for a planned conception.

The Evidence Gap: What We Do Not Yet Know

Women have been under-represented in dermatology trials for decades, and FPHL research is no exception. The Sinclair 2018 cohort, the most-cited oral minoxidil dataset, had only 100 women and no control arm. Spironolactone FPHL data are largely retrospective with no placebo comparator for hair endpoints (though the SAHA trial does provide RCT-level evidence for acne).

A 2023 Cochrane-linked systematic review on interventions for FPHL explicitly noted the absence of adequately powered, placebo-controlled trials comparing oral minoxidil and spironolactone. What we have is mechanistic logic, separate-arm cohort data, and clinician experience. A large head-to-head RCT in women, stratified by androgen status, does not yet exist.

Any prescriber or article telling you definitively that one drug beats the other is working beyond the current evidence. The honest answer: both work, the choice depends on your biology and goals, and the field needs better trials.